eMedicine Specialties > Hematology > Coagulation, Hemostasis, and Disorders

Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits

Author: Rodger L Bick, MD, PhD, FACP, Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas and Pacific Thrombosis Hemostasis and Vascular Medicine Clinical Center
Contributor Information and Disclosures

Updated: Jul 1, 2008

Introduction

Background

Recurrent miscarriage syndrome (RMS) is a common obstetric problem, affecting over 500,000 women in the United States per year1 ; infertility, although less well defined epidemiologically, is also a common clinical problem.

For excellent patient education resources, visit eMedicine's Women's Health Center and Pregnancy and Reproduction Center. Also, see eMedicine's patient education articles Miscarriage, Threatened Miscarriage, and Infertility.

Pathophysiology

RMS due to blood protein or platelet defects may come about through 2 mechanisms: (1) those disorders that are associated with a hemorrhagic tendency or (2) those defects that are associated with a thrombotic tendency. Hemorrhagic (bleeding) defects that are associated with RMS are rare, whereas thrombotic or hypercoagulable/thrombophilic defects are extremely common.2,3 The hemorrhagic defects associated with fetal wastage syndrome presumably lead to inadequate fibrin formation, thus precluding adequate implantation of the fertilized ovum into the uterus.

Frequency

United States

RMS affects more than 500,000 women in the United States per year.1

Race

Females of any race can be affected by RMS.

Sex

Only females are affected by RMS.

Age

Females of childbearing age

Clinical

History

Patients have a history of 2 or more miscarriages. They may or may not have a history of bleeding (see Workup, Lab Studies).

Physical

The physical examination is usually normal, unless maternal thrombosis is present.

Causes

Blood coagulation protein and platelet defects

The hemorrhagic defects associated with fetal wastage syndrome include factor XIII deficiency or polymorphism,3,4,5 factor XII defects,6 factor X deficiency,7 factor VII deficiency,8 factor V deficiency,9 factor II (prothrombin) deficiency,10 von Willebrand syndrome, and carrier state for hemophilia and fibrinogen defects (including afibrinogenemia), and those dysfibrinogenemias associated with hemorrhage and others.11,12,13,14,15,16,17

Management of these patients is generally plasma substitution therapy or, in appropriate disorders, DDAVP (vasopressin) therapy.1,2 Hemorrhagic or bleeding defects are rare causes of recurrent miscarriage relative to thrombotic or thrombophilic disorders.1,2,18

The thrombotic defects associated with fetal wastage occur due to thrombosis of early placental vessels, with peak fetal wastage in the first trimester, but small peaks also occur in the second and third trimesters.1,19 The earlier the pregnancy, the smaller the placental and uterine vessels and, therefore, the greater the propensity to undergo partial or total occlusion by thrombus formation. Thrombotic occlusion of placental vessels, both venous and arterial, preclude adequate nutrition and, thus, viability of the fetus.1,2

The thrombotic hemostasis defects associated with recurrent miscarriage syndrome include lupus anticoagulants and anticardiolipin antibodies (these 2 comprise the antiphospholipid syndromes [APLSs] that are associated with fetal wastage syndrome),20,21,22 factor XII deficiency,23 dysfibrinogenemias associated with thrombosis,24 protein C defects,25 protein S defects, antithrombin deficiency,26 heparin cofactor II deficiency,27 and fibrinolytic defects that are associated with thrombosis (including plasminogen deficiency,28 tissue plasminogen activator [t-PA or TPA] deficiency, elevated plasminogen activator inhibitor type 1 [PAI-1],29 and PAI-1 polymorphisms30 ).

Also, although sticky platelet syndrome has been known for over a decade and leads to a wide variety of arterial and venous events, only in the past several years has it become apparent that this defect is a common cause of RMS.19 In addition, like other new defects (including factor V Leiden; 5,10-methyltetrahydrofolate reductase mutations [5,10-MTHFR], and prothrombin G20210A gene mutation), sticky platelet syndrome should be added to the prothrombotic disorders that are associated with RMS.2 As new procoagulant factor mutations associated with hypercoagulability and thrombosis are discovered, they, too, are anticipated to be found associated with placental thrombosis and RMS in many cases.

The following list summarizes the bleeding disorders which may give rise to recurrent RMS or infertility; these are very rare causes as compared with prothrombotic disorders.

Bleeding disorders that are associated with RMS (rare) include the following:

  • Factor XIII deficiency
  • von Willebrand disease
  • Factor X deficiency
  • Factor VII deficiency
  • Factor V deficiency
  • Factor II deficiency
  • Hypofibrinogenemia
  • Dysfibrinogenemia
  • Hemophilia A carrier status
The list below summarizes the hypercoagulable, prothrombotic disorders that lead to or potentially lead to RMS or infertility by inducing placental or uterine arterial or venous thrombosis; these defects are common causes of RMS and infertility.

Thrombotic disorders associated with RMS (common) include the following:

[#APLS]Procoagulant defects

APLS is clearly the most common thrombotic defect leading to fetal wastage syndrome, infertility, or both, and various treatment programs have been advocated.31 One difficulty in evaluating these programs has been that some populations have addressed primarily patients with secondary APLS and fetal wastage, in particular those with underlying systemic lupus erythematosus or other autoimmune disorders. Only a few investigators have addressed populations with primary APLS who have no known underlying disease.

APLS has long been recognized as a cause of miscarriage and infertility; it has also long been recognized that treatment for this condition is often successful.32 Many clinicians consider APLS to be the most common prothrombotic disorder among both hereditary and acquired defects, as well as the most common thrombotic disorder causing recurrent miscarriage.1,2,20,21,33,34,35,36,37

When assessing causes of infertility alone, APLS is thought to account for about 30% of infertility cases; however, in one series, abnormal CD56+/CD16 cell ratios were the single most common defect found (40%) in infertility patients.38 In another series, only 21% of patients with RMS had APLS; however, when assessing historically women with APLS, 80% had suffered at least one miscarriage.39,31

In a series reported by Granger and Farquharson, 387 unselected patients were assessed for APLS. Of these, 16% harbored APLS, and of those with APLS, 56% had a term delivery with low-dose aspirin (ASA).40 Borelli et al found that 60% of their studied patients with "habitual" unexplained miscarriage had APLS.41 Although the great majority of cases of APLS are clearly acquired,20,36 familial APLS that is associated with RMS has been reported.42 Clearly, however, screening for APLS is indicated in patients with RMS.1,2,20,21,33,34,36,43

One study has suggested that monitoring miscarriage patients with APLS by use of prothrombin fragment 1.2 may predict preclinical placental thrombi44 ; if this finding is confirmed, it may preclude the necessity of frequent sonograms, which is the current mode of careful monitoring for pregnant patients who have had RMS and who are on therapy. In addition, because APLS is very common and because many of the hereditary thrombophilias, such as factor V Leiden, are very prevalent in North America, it is not unexpected that some women with RMS have APLS in combination with other procoagulant defects. Aznar et al reported a case of RMS that was complicated by deep venous thrombosis (DVT) and thrombotic stroke in a patient with APLS, factor V Leiden, and congenital protein S deficiency.45

Many mechanisms have been proposed whereby APLS interferes with the hemostasis system and predisposes to thrombosis.1,2,3,20,21,33,34,35,36,43 However, some investigators have proposed mechanisms that are specific for RMS. These proposed mechanisms have included the proposal that APLSs induce acquired activated protein C resistance (APC-R),45 as well as interferes with prothrombin (factor II), protein C and protein S, tissue factor, factor XI,46 and the tissue factor/tissue factor pathway inhibitor (TF/TFPI) system.47 Another study also found that patients with APLS harbored antibodies to prothrombin, protein C, and protein S.48 Other investigators have proposed these patients may also develop antibodies to "thromboplastin" and thrombin.49

Another proposed mechanism is that APLSs interfere with annexin-V (also referred to as placental anticoagulant protein, serine only).50 Three studies demonstrated immunoglobulin (Ig) fractions of antiphospholipid antibody (APLA) or beta2-glycoprotein-1 (B2GP1) decrease trophoblastic annexin-V50,51,52 , but several studies have shown this anti–annexin-V activity to be limited to the antiphosphatidylserine subgroup antibody idiotype.53,54 On rare occasions, APLS may be inherited (this author has seen 3 such families) and others have been reported,42 suggesting that a positive maternal history may warrant evaluation at first pregnancy, as should a history of familial thrombosis.

Patients with other congenital or acquired thrombophilic states are also at high risk for placental thrombosis and RMS. In a study that assessed a variety of these defects in 46 selected women with RMS (anatomic and hormone defects were ruled out before the hemostasis assessment), the following was found: 76% had anticardiolipin antibodies (void of lupus anticoagulants), 3% had a lupus anticoagulant (void of anticardiolipin antibodies), 11% had congenital protein S deficiency (3 quantitative; 1 dysfunctional), 6.5% had sticky platelet syndrome (2 with type I; 1 with type II), 3% had dysfibrinogenemia, and 3% had congenital TPA deficiency.19

In a study that assessed the prevalence of hereditary and acquired defects in patients with RMS, 9.4% had isolated factor XII deficiency and 7.4% had APLS; fibrinolytic system defects, leading to hypofibrinolysis and hypercoagulability, were found in 42.6% of patients.55 This study concluded that von Willebrand disease, fibrinogen deficiency, antithrombin deficiency, protein C and protein S deficiency, TPA deficiency, and PAI-1 defects played no role in RMS.55

However, in a similar study assessing hereditary hemostasis defects in 125 patients with RMS, quite different results were noted, and factor V Leiden mutation was found in 14%.56 However, in another study of 50 patients with RMS, it was concluded that factor V Leiden, prothrombin G20210A mutation, and 5,10-MTHFR mutations were not causes of RMS.57 Bokarewa et al also noted in their study that although factor V Leiden was responsible for a greater than 3-fold risk of DVT, there was no association with miscarriage.58

Yet Brenner et al revealed that factor V Leiden was responsible for 48% of recurrent miscarriages,59 and Rai et al reported that factor V Leiden was associated with a high incidence of second-trimester miscarriages in their series.60 An additional 2 studies clearly showed an association between factor V Leiden mutation and recurrent miscarriages.61,62 Thus, the preponderance of evidence certainly strongly suggests that heterozygous factor V Leiden mutation is a significant risk factor for recurrent miscarriage and increases the risk for miscarriage by at least 3.3-fold.59

Another common thrombophilic disorder, prothrombin G20210A gene mutation, was described by Poort and associates in 1996.63 Although Kutteh et al found no association between this mutation and RMS,57 a study by Brenner et al found an increased 2.2-fold risk of recurrent miscarriage in women with this genetic procoagulant defect.64

Another hereditary defect that leads to hypercoagulability and thrombosis is 5,10-MTHFR C677T mutation. Although Kutteh et al found no association between this defect and recurrent miscarriage,57 Brenner et al showed a clear association between heterozygosity for this mutation and recurrent miscarriage, with those who harbor the mutation having a 2-fold enhanced risk of miscarriage.64

Finally, although hypofibrinolysis in general has been shown to be associated with recurrent miscarriage,29 only recently has the role of PAI-1 elevation and PAI-1 polymorphism or polymorphisms been shown as a cause of RMS.30 Potential and proposed mechanisms of antiphospholipid antibody-induced thrombosis (APL-T) are summarized in the list below.

Proposed mechanisms of thrombosis APL-T syndromes include the following:

  • Interference with endothelial phospholipids and, thus, prostacyclin release
  • Inhibition of prekallikrein and, thus, inhibition of fibrinolysis
  • Inhibition of thrombomodulin, thus, protein C/S activity
  • APC-R (nonmolecular)
  • Interaction with platelet membrane phospholipids
  • Inhibition of endothelial TPA release
  • Direct inhibition of protein S
  • Inhibition of annexin-V, or placental anticoagulant protein (serine only), a cell-surface protein that inhibits tissue factor
  • Induce release of monocyte tissue factor

More on Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits

Overview: Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits
Differential Diagnoses & Workup: Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits
Treatment & Medication: Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits
Follow-up: Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits
Multimedia: Miscarriages Caused by Blood Coagulation Protein or Platelet Deficits
References
[ CLOSE WINDOW ]

References

  1. Bick RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein or platelet defects. Hematol Oncol Clin North Am. Oct 2000;14(5):1117-31. [Medline].

  2. Redline RW. Thrombophilia and placental pathology. Clin Obstet Gynecol. Dec 2006;49(4):885-94. [Medline].

  3. López Ramírez Y, Vivenes M, Miller A, et al. Prevalence of the coagulation factor XIII polymorphism Val34Leu in women with recurrent miscarriage. Clin Chim Acta. Dec 2006;374(1-2):69-74. [Medline].

  4. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, et al. Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clin Chem. Jul 2003;49(7):1081-6. [Medline]. [Full Text].

  5. Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood coagulation factor XIII deficiency and successful deliveries: a review of the literature. Obstet Gynecol Surv. Apr 2007;62(4):255-60. [Medline].

  6. Matsubayashi H, Sugi T, Suzuki T, et al. Decreased factor XII activity is associated with recurrent IVF-ET failure. Am J Reprod Immunol. Apr 2008;59(4):316-22. [Medline].

  7. Valnícek S, Vacl J, Mrázová M, et al. [Hemotherapeutic safeguarding of induced abortion in inborn proconvertin insufficiency (hemagglutination factor VII) using exchange plasmapheresis] [German]. Zentralbl Gynakol. Jul 22 1972;94(29):931-5. [Medline].

  8. Nelson DB, Ness RB, Grisso JA, Cushman M. Influence of hemostatic factors on spontaneous abortion. Am J Perinatol. Jun 2001;18(4):195-201. [Medline].

  9. Slunský R. [Personal experiences with the antifibrinolytic PAMBA in obstetrics and gynecology] [German]. Zentralbl Gynakol. Mar 21 1970;92(12):364-7. [Medline].

  10. Owen CA Jr, Henriksen RA, McDuffie FC, Mann KG. Prothrombin Quick. A newly identified dysprothrombinemia. Mayo Clin Proc. Jan 1978;53(1):29-33. [Medline].

  11. Pauer HU, Burfeind P, Köstering H, Emons G, Hinney B. Factor XII deficiency is strongly associated with primary recurrent abortions. Fertil Steril. Sep 2003;80(3):590-4. [Medline].

  12. Jones DW, Gallimore MJ, Winter M. Antibodies to factor XII: a possible predictive marker for recurrent foetal loss. Immunobiology. 2003;207(1):43-6. [Medline].

  13. Sugi T, Makino T. Antiphospholipid antibodies and kininogens in pathologic pregnancies: a review. Am J Reprod Immunol. May 2002;47(5):283-8. [Medline].

  14. Iinuma Y, Sugiura-Ogasawara M, Makino A, Ozaki Y, Suzumori N, Suzumori K. Coagulation factor XII activity, but not an associated common genetic polymorphism (46C/T), is linked to recurrent miscarriage. Fertil Steril. Feb 2002;77(2):353-6. [Medline].

  15. Yamada H, Kato EH, Ebina Y, et al. Factor XII deficiency in women with recurrent miscarriage. Gynecol Obstet Invest. 2000;49(2):80-3. [Medline].

  16. Evron S, Anteby SO, Brzezinsky A, Samueloff A, Eldor A. Congenital afibrinogenemia and recurrent early abortion: a case report. Eur J Obstet Gynecol Reprod Biol. May 1985;19(5):307-11. [Medline].

  17. Mammen EF. Congenital abnormalities of the fibrinogen molecule. Semin Thromb Hemost. 1974;1:184.

  18. Bick RL. Antiphospholipid syndrome in pregnancy. Hematol Oncol Clin North Am. Feb 2008;22(1):107-20, vii. [Medline].

  19. Bick RL, Laughlin HR, Cohen B, et al. Fetal wastage syndrome due to blood protein/platelet defects: results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin. Clin Appl Thromb Hemost. 1995;1:286.

  20. Bick RL, Baker WF. Antiphospholipid syndrome and thrombosis. Semin Thromb Hemost. 1999;25(3):333-50. [Medline].

  21. Bick RL. The antiphospholipid thrombosis syndromes: a common multidisciplinary medical problem. Clin Appl Thromb Hemost. 1997;3:270.

  22. Scott JR, Rote NS, Branch DW. Immunologic aspects of recurrent abortion and fetal death. Obstet Gynecol. Oct 1987;70(4):645-56. [Medline].

  23. Schved JF, Gris JC, Neveu S, Dupaigne D, Mares P. Factor XII congenital deficiency and early spontaneous abortion. Fertil Steril. Aug 1989;52(2):335-6. [Medline].

  24. Klein M, Rosen A, Kyrle P, Beck A. [Obstetrical management of dysfibrinogenemia with increased thrombophilia] [German]. Geburtshilfe Frauenheilkd. Jul 1992;52(7):442-4. [Medline].

  25. Barkagan ZS, Belykh SI. [Protein C deficiency and the multi-thrombotic syndrome associated ith pregnancy and abortion] [Russian]. Gematol Transfuziol. Sep-Oct 1992;37(9-10):35-7. [Medline].

  26. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest. 1982;14(2):127-41. [Medline].

  27. Simioni P, Lazzaro AR, Coser E, Salmistraro G, Girolami A. Hereditary heparin cofactor II deficiency and thrombosis: report of six patients belonging to two separate kindreds. Blood Coagul Fibrinolysis. Oct 1990;1(4-5):351-6. [Medline].

  28. Satoh A, Suzuki K, Takayama E, et al. Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Rheumatol. Aug 1999;26(8):1715-20. [Medline].

  29. Gris JC, Neveu S, Mares P, et al. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. J Lab Clin Med. Nov 1993;122(5):606-15. [Medline].

  30. Glueck CJ, Wang P, Fontaine RN, et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. Dec 1999;48(12):1589-95. [Medline].

  31. Bick RL, Hoppensteadt D. Recurrent miscarriage syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin Appl Thromb Hemost. Jan 2005;11(1):1-13. [Medline].

  32. Khamashta MA. Management of thrombosis and pregnancy loss in the antiphospholipid syndrome. Lupus. 1998;7 suppl 2:S162-5. [Medline].

  33. Amengual O, Atsumi T, Khamashta MA, Hughes GR. Advances in antiphospholipid (Hughes') syndrome. Ann Acad Med Singapore. Jan 1998;27(1):61-6. [Medline].

  34. Bick RL. Antiphospholipid thrombosis syndromes: etiology, pathophysiology, diagnosis and management. Int J Hematol. Apr 1997;65(3):193-213. [Medline].

  35. Bick RL, Baker WF Jr. The antiphospholipid and thrombosis syndromes. Med Clin North Am. May 1994;78(3):667-84. [Medline].

  36. Bick RL. Recurrent miscarriage syndrome and infertility caused by blood coagulation protein/platelet defects. In: Bick RL, Frenkel EP, Baker WF, Sarode R, eds. Hematologic Complications in Obstetrics, Pregnancy, and Gynecology. Cambridge, UK: Cambridge University Press; 2006:55-74.

  37. Festin MR, Limson GM, Maruo T. Autoimmune causes of recurrent pregnancy loss. Kobe J Med Sci. Oct 1997;43(5):143-57. [Medline].

  38. Roussev RG, Kaider BD, Price DE, Coulam CB. Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol. Apr 1996;35(4):415-20. [Medline].

  39. Oshiro BT, Silver RM, Scott JR, Yu H, Branch DW. Antiphospholipid antibodies and fetal death. Obstet Gynecol. Apr 1996;87(4):489-93. [Medline].

  40. Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus. 1997;6(6):509-13. [Medline].

  41. Borrelli AL, Brillante M, Borzacchiello C, Berlingieri P. Hemocoagulative pathology and immunological recurrent abortion. Clin Exp Obstet Gynecol. 1997;24(1):39-40. [Medline].

  42. Hellan M, Kühnel E, Speiser W, Lechner K, Eichinger S. Familial lupus anticoagulant: a case report and review of the literature. Blood Coagul Fibrinolysis. Mar 1998;9(2):195-200. [Medline].

  43. Ogasawara M, Aoki K, Matsuura E, Sasa H, Yagami Y. Anti beta 2 glycoprotein I antibodies and lupus anticoagulant in patients with recurrent pregnancy loss: prevalence and clinical significance. Lupus. Dec 1996;5(6):587-92. [Medline].

  44. Zangari M, Lockwood CJ, Scher J, Rand JH. Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies. Thromb Res. Feb 1 1997;85(3):177-83. [Medline].

  45. Aznar J, Villa P, España F, et al. Activated protein C resistance phenotype in patients with antiphospholipid antibodies. J Lab Clin Med. Aug 1997;130(2):202-8. [Medline].

  46. Schultz DR. Antiphospholipid antibodies: basic immunology and assays. Semin Arthritis Rheum. Apr 1997;26(5):724-39. [Medline].

  47. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. Feb 1998;79(2):276-81. [Medline].

  48. Martini A, Ravelli A. The clinical significance of antiphospholipid antibodies. Ann Med. Apr 1997;29(2):159-63. [Medline].

  49. Bussen SS, Steck T. Thyroid antibodies and their relation to antithrombin antibodies, anticardiolipin antibodies and lupus anticoagulant in women with recurrent spontaneous abortions (antithyroid, anticardiolipin and antithrombin autoantibodies and lupus anticoagulant in habitual aborters). Eur J Obstet Gynecol Reprod Biol. Aug 1997;74(2):139-43. [Medline].

  50. Rand JH, Wu XX. Antibody-mediated disruption of the annexin-V antithrombotic shield: a new mechanism for thrombosis in the antiphospholipid syndrome. Thromb Haemost. Aug 1999;82(2):649-55. [Medline]. [Full Text].

  51. Rand JH, Wu XX, Andree HA, et al. Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood. Sep 1 1998;92(5):1652-60. [Medline]. [Full Text].

  52. Rauch J. Lupus anticoagulant antibodies: recognition of phospholipid-binding protein complexes. Lupus. 1998;7 suppl 2:S29-31. [Medline].

  53. Rote NS, Vogt E, DeVere G, Obringer AR, Ng AK. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol. Feb 1998;39(2):125-36. [Medline].

  54. Vogt E, Ng AK, Rote NS. Antiphosphatidylserine antibody removes annexin-V and facilitates the binding of prothrombin at the surface of a choriocarcinoma model of trophoblast differentiation. Am J Obstet Gynecol. Oct 1997;177(4):964-72. [Medline].

  55. Gris JC, Ripart-Neveu S, Maugard C, et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost. Jun 1997;77(6):1096-103. [Medline].

  56. Tal J, Schliamser LM, Leibovitz Z, Ohel G, Attias D. A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod. Jun 1999;14(6):1624-7. [Medline]. [Full Text].

  57. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril. Jun 1999;71(6):1048-53. [Medline].

  58. Bokarewa MI, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. Feb 1996;92(2):473-8. [Medline].

  59. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol. Jun 1997;97(3):551-4. [Medline].

  60. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol. Feb 1996;92(2):489-90. [Medline].

  61. Grandone E, Margaglione M, Colaizzo D, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost. May 1997;77(5):822-4. [Medline].

  62. Ridker PM, Miletich JP, Buring JE, et al. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss. Ann Intern Med. Jun 15 1998;128(12 pt 1):1000-3. [Medline]. [Full Text].

  63. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. Nov 15 1996;88(10):3698-703. [Medline]. [Full Text].

  64. Brenner B, Sarig G, Weiner Z, et al. Thrombophilic polymorphisms are common in women with fetal loss without apparent cause. Thromb Haemost. Jul 1999;82(1):6-9. [Medline]. [Full Text].

  65. Sher G, Feinman M, Zouves C, et al. High fecundity rates following in-vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod. Dec 1994;9(12):2278-83. [Medline].

  66. Rosove MH, Tabsh K, Wasserstrum N, et al. Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol. Apr 1990;75(4):630-4. [Medline].

  67. Brown HL. Antiphospholipid antibodies and recurrent pregnancy loss. Clin Obstet Gynecol. Mar 1991;34(1):17-26. [Medline].

  68. Perino A, Barba G, Cimino C, et al. Immunological problems in the recurrent abortion syndrome. Acta Eur Fertil. Jul-Aug 1989;20(4):199-202. [Medline].

  69. Many A, Pauzner R, Carp H, Langevitz P, Martinowitz U. Treatment of patients with antiphospholipid antibodies during pregnancy. Am J Reprod Immunol. Oct-Dec 1992;28(3-4):216-8. [Medline].

  70. Lubbe WF, Liggins GC. Role of lupus anticoagulant and autoimmunity in recurrent fetal loss. Semin Reprod Endocrinol. 1988;6:181-90.

  71. Lin QD. [Investigation of the association between autoantibodies and recurrent abortions] [Chinese]. Zhonghua Fu Chan Ke Za Zhi. Nov 1993;28(11):674-7, 702. [Medline].

  72. Cowchock FS, Reece EA, Balaban D, Branch DW, Plouffe L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. May 1992;166(5):1318-23. [Medline].

  73. Landy HJ, Kessler C, Kelly WK, Weingold AB. Obstetric performance in patients with the lupus anticoagulant and/or anticardiolipin antibodies. Am J Perinatol. May 1992;9(3):146-51. [Medline].

  74. Semprini AE, Vucetich A, Garbo S, Agostoni G, Pardi G. Effect of prednisone and heparin treatment in 14 patients with poor reproductive efficiency related to lupus anticoagulant. Fetal Ther. 1989;4 suppl 1:73-6. [Medline].

  75. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. May 1996;174(5):1584-9. [Medline].

  76. Parke A. The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. Clin Rev Allergy. Spring-Summer 1992;10(1-2):105-18. [Medline].

  77. Toschi V, Motta A, Castelli C, et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke. Sep 1998;29(9):1759-64. [Medline]. [Full Text].

  78. España F, Villa P, Mira Y, et al. Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion. Haematologica. Jan 1999;84(1):80-4. [Medline]. [Full Text].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

recurrent miscarriage, recurrent miscarriage syndrome, RMS, fetal wastage syndrome, recurrent fetal loss, antiphospholipid syndrome, APLS, factor XIII deficiency, factor XII defects, factor X deficiency, factor VII deficiency, factor V deficiency, factor V Leiden, factor II (prothrombin) deficiency, von Willebrand syndrome, hemophilia, fibrinogen defects, afibrinogenemia, sticky platelet syndrome,

5,10-methyltetrahydrofolate reductase mutations, MTHFR mutations, C677T, hyperhomocysteinemia, PAI-1 elevation / polymorphisms, protein S deficiency, prothrombin G20210A,protein C deficiency, antithrombin deficiency, heparin cofactor II deficiency, tissue plasminogen activator deficiency, TPA deficiency, lipoprotein (a), immune vasculitis, annexin-V, annexin V, placental anticoagulant protein, dalteparin, Fragmin

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Rodger L Bick, MD, PhD, FACP, Clinical Professor of Medicine, University of Texas Southwestern Medical Center; Director, Dallas and Pacific Thrombosis Hemostasis and Vascular Medicine Clinical Center
Rodger L Bick, MD, PhD, FACP is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Association of Blood Banks, American Cancer Society, American College of Angiology, American College of Physicians, American Geriatrics Society, American Heart Association, American Medical Association, American Society for Clinical Pathology, American Society of Hematology, Association of Clinical Scientists, California Medical Association, California Thoracic Society, International College of Angiology, International Society of Hematology, International Society on Thrombosis and Haemostasis, New York Academy of Sciences, and Southwest Oncology Group
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

Managing Editor

Ronald A Sacher, MB, BCh, MD, FRCPC, Professor, Internal Medicine and Pathology, Director, Hoxworth Blood Center, University of Cincinnati Academic Health Center
Ronald A Sacher, MB, BCh, MD, FRCPC is a member of the following medical societies: American Society of Hematology
Disclosure: Glaxo Smith Kline Honoraria Speaking and teaching; Talecris Honoraria Board membership

CME Editor

Rajalaxmi McKenna, MD, FACP, Southwest Medical Consultants, SC, Department of Medicine, Good Samaritan Hospital, Advocate Health Systems
Rajalaxmi McKenna, MD, FACP is a member of the following medical societies: American Society of Clinical Oncology, American Society of Hematology, and International Society on Thrombosis and Haemostasis
Disclosure: Nothing to disclose.

Chief Editor

Emmanuel C Besa, MD, Professor, Department of Medicine, Division of Hematologic Malignancies, Kimmel Cancer Center, Thomas Jefferson University
Emmanuel C Besa, MD is a member of the following medical societies: American Association for Cancer Education, American College of Clinical Pharmacology, American Federation for Medical Research, American Society of Hematology, and New York Academy of Sciences
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.